Levemir use extended

The licence for Levemir (insulin detemir) has been extended to include use in combination with oral hypoglycaemic agents in the treatment of diabetes.

When used in combination with oral hypoglycaemics, Levemir should be initiated at  10iu or 0.1–0.2iu/kg once daily and titrated according to individual patient requirements. When initiating therapy with Levemir, concomitant antidiabetic treatment may need to be adjusted, including the dose and/or timing of oral hypoglycaemics or concurrent short- or rapid-acting insulins.

According to the product labelling, in three clinical studies, a higher frequency of allergic reactions, and potential allergic reactions, was observed in patients treated with Levemir in combination with oral hypoglycaemic agents.

Further information: Novo Nordisk 0845 6005055

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more